Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 335

1.

Spectrum of CD30+ lymphoid proliferations in the eyelid lymphomatoid papulosis, cutaneous anaplastic large cell lymphoma, and anaplastic large cell lymphoma.

Sanka RK, Eagle RC Jr, Wojno TH, Neufeld KR, Grossniklaus HE.

Ophthalmology. 2010 Feb;117(2):343-51. doi: 10.1016/j.ophtha.2009.07.013. Epub 2009 Dec 6.

2.

Intralymphatic cutaneous anaplastic large cell lymphoma/lymphomatoid papulosis: expanding the spectrum of CD30-positive lymphoproliferative disorders.

Samols MA, Su A, Ra S, Cappel MA, Louissant A Jr, Knudson RA, Ketterling RP, Said J, Binder S, Harris NL, Feldman AL, Kim J, Kim YH, Gratzinger D.

Am J Surg Pathol. 2014 Sep;38(9):1203-11. doi: 10.1097/PAS.0000000000000217.

PMID:
24805854
4.

Specificity of IRF4 translocations for primary cutaneous anaplastic large cell lymphoma: a multicenter study of 204 skin biopsies.

Wada DA, Law ME, Hsi ED, Dicaudo DJ, Ma L, Lim MS, Souza Ad, Comfere NI, Weenig RH, Macon WR, Erickson LA, Ozsan N, Ansell SM, Dogan A, Feldman AL.

Mod Pathol. 2011 Apr;24(4):596-605. doi: 10.1038/modpathol.2010.225. Epub 2010 Dec 17.

5.

Galectin-3 Expression in Primary Cutaneous CD30-Positive Lymphoproliferative Disorders and Transformed Mycosis Fungoides.

Mitteldorf C, Robson A, Tronnier M, Pfaltz MC, Kempf W.

Dermatology. 2015;231(2):164-70. doi: 10.1159/000431313. Epub 2015 Jun 20.

6.

CD30+ lymphoproliferative disorder: primary cutaneous anaplastic large cell lymphoma followed by lymphomatoid papulosis.

Aoki M, Niimi Y, Takezaki S, Azuma A, Seike M, Kawana S.

Br J Dermatol. 2001 Jul;145(1):123-6.

PMID:
11453920
7.

The differential diagnosis of CD8-positive ("type D") lymphomatoid papulosis.

McQuitty E, Curry JL, Tetzlaff MT, Prieto VG, Duvic M, Torres-Cabala C.

J Cutan Pathol. 2014 Feb;41(2):88-100. doi: 10.1111/cup.12243. Epub 2013 Oct 30.

PMID:
24118002
8.

Intralymphatic Spread Is a Common Finding in Cutaneous CD30+ Lymphoproliferative Disorders.

Ferrara G, Ena L, Cota C, Cerroni L.

Am J Surg Pathol. 2015 Nov;39(11):1511-7. doi: 10.1097/PAS.0000000000000474.

PMID:
26371781
9.
10.

Loss of expression of 5-hydroxymethylcytosine in CD30-positive cutaneous lymphoproliferative disorders.

De Souza A, Tinguely M, Pfaltz M, Burghart DR, Kempf W.

J Cutan Pathol. 2014 Dec;41(12):901-6. doi: 10.1111/cup.12411. Epub 2014 Nov 25.

PMID:
25353265
11.

Multiple cutaneous lymphoproliferative disorders showing a retained tumor clone by T-cell receptor gene rearrangement analysis: a case series of four patients and review of the literature.

Stowman AM, Hsia LL, Kanner WA, Mahadevan MS, Bullock GC, Patterson JW.

Int J Dermatol. 2016 Feb;55(2):e62-71. doi: 10.1111/ijd.12847. Epub 2015 Aug 12. Review.

PMID:
26266670
12.

Death receptor apoptosis signaling mediated by FADD in CD30-positive lymphoproliferative disorders involving the skin.

Clarke LE, Bayerl MG, Bruggeman RD, Mauger D, Ioffreda MD, Abou-Elella A, Helm KF.

Am J Surg Pathol. 2005 Apr;29(4):452-9.

PMID:
15767797
13.

MUM1 expression in cutaneous CD30+ lymphoproliferative disorders: a valuable tool for the distinction between lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma.

Kempf W, Kutzner H, Cozzio A, Sander CA, Pfaltz MC, Müller B, Pfaltz M.

Br J Dermatol. 2008 Jun;158(6):1280-7. doi: 10.1111/j.1365-2133.2008.08566.x. Epub 2008 Apr 10.

PMID:
18410414
14.

Primary cutaneous CD30 positive T-cell lymphoproliferative disorders with aberrant expression of PAX5: report of three cases.

Hagiwara M, Tomita A, Takata K, Shimoyama Y, Yoshino T, Tomita Y, Nakamura S.

Pathol Int. 2012 Apr;62(4):264-70. doi: 10.1111/j.1440-1827.2011.02784.x. Epub 2012 Jan 30.

PMID:
22449230
15.

Expression of CD44 and CD44v6 in primary cutaneous CD30 positive T-cell lymphoproliferative disorders.

Liang X, Smoller BR, Golitz LE.

J Cutan Pathol. 2002 Sep;29(8):459-64.

PMID:
12207739
16.

[Primary cutaneous CD30+ lymphoproliferative disorders].

Calzado-Villarreal L, Polo-Rodríguez I, Ortiz-Romero PL.

Actas Dermosifiliogr. 2010 Mar;101(2):119-28. Review. Spanish.

PMID:
20223154
17.

Practical Management of CD30⁺ Lymphoproliferative Disorders.

Hughey LC.

Dermatol Clin. 2015 Oct;33(4):819-33. doi: 10.1016/j.det.2015.05.013. Epub 2015 Aug 29. Review.

18.

Contribution of longitudinal follow up and clinical pathological correlation in the diagnosis CD30-positive skin infiltrates.

De Souza A, Carter JB, Harris NL, Ferry JA, Duncan LM.

J Cutan Pathol. 2015 Jul;42(7):452-8. doi: 10.1111/cup.12510. Epub 2015 Jun 4.

PMID:
25931140
19.

Diagnostic and prognostic evaluation of phenotypic markers TRAF1, MUM1, BCL2 and CD15 in cutaneous CD30-positive lymphoproliferative disorders.

Benner MF, Jansen PM, Meijer CJ, Willemze R.

Br J Dermatol. 2009 Jul;161(1):121-7. doi: 10.1111/j.1365-2133.2009.09147.x. Epub 2009 Apr 16.

PMID:
19416236
20.

Epstein-Barr virus in CD30 anaplastic large cell lymphoma involving the skin and lymphomatoid papulosis in South Korea.

Kim YC, Yang WI, Lee MG, Kim SN, Cho KH, Lee SJ, Lee MW, Koh JK.

Int J Dermatol. 2006 Nov;45(11):1312-6.

PMID:
17076712

Supplemental Content

Support Center